Clinical Trials

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

38 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

9 enrolled

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04879329 2026-01-07

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

372 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03288545 2025-11-10

EV-103

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1/2 Recruiting

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05923190 2025-10-29

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

70 enrolled

Carcinoma, Transitional Cell

NCT04344795 2025-09-12

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

89 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms

NCT05845814 2025-09-10

MK-3475-04B

390 enrolled

Carcinoma, Transitional Cell

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase 3 Completed

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DermatologicGenitourinaryHead & NeckThoracic

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05585034 2025-08-07

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

60 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05406713 2025-06-10

Pembrolizumab in Muscle-invasive Bladder Cancer

Phase 2 Active not recruiting

46 enrolled

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT02717156 2025-06-05

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

103 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Transitional Cell, Prostatic Neoplasms

NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Phase 1/2 Completed

40 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

700 enrolled

Carcinoma, Transitional Cell

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Carcinoma, Transitional Cell

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Phase 1/2 Completed

323 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT03240016 2025-01-16

ABLE

Phase 2 Completed

36 enrolled 14 charts

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04637594 2025-01-15

IMAGINE

3 enrolled

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

48 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03486197 2024-11-20

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

Phase 2 Terminated

12 enrolled 10 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Transitional Cell

NCT03809624 2024-10-23

PDL1x41BB

Phase 1 Terminated

160 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Oropharyngeal Neoplasms, Stomach Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

263 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

GastrointestinalGenitourinaryThoracic

175 enrolled 23 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06270706 2024-06-12

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Unknown

77 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03311334 2024-04-18

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1/2 Terminated

47 enrolled 11 charts

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Kidney Neoplasms, Wilms Tumor, Ovarian Neoplasms

NCT05894447 2024-04-12

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies